Ph.D John Woock - 15 Nov 2021 Form 4 Insider Report for Axonics, Inc.

Role
Chief Marketing Officer
Signature
/s/ Dan Dearen, as Attorney-in-Fact for John Woock, Ph.D
Issuer symbol
N/A
Transactions as of
15 Nov 2021
Net transactions value
-$231,471
Form type
4
Filing time
17 Nov 2021, 20:16:15 UTC
Previous filing
03 Sep 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXNX Common Stock Options Exercise $70,950 +5,000 +20% $14.19* 29,932 15 Nov 2021 Direct
transaction AXNX Common Stock Sale $121,209 -2,016 -6.7% $60.12 27,916 15 Nov 2021 Direct F1, F2
transaction AXNX Common Stock Sale $181,212 -2,984 -11% $60.73 24,932 15 Nov 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXNX Stock Option (Right to Buy) Options Exercise $0 -5,000 -14% $0.000000 30,555 15 Nov 2021 Common Stock 5,000 $14.19 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was pursuant to a 10b5-1 plan adopted by the reporting person on June 15, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $59.54 to $60.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $60.57 to $60.835. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date.